Compare
Lineage Cell Therapeutics, Inc. vs Caribou Biosciences, Inc. vs LENZ Therapeutics, Inc. vs TScan Therapeutics, Inc.
| Latest fiscal year | Lineage Cell Therapeutics, Inc. LCTX | Caribou Biosciences, Inc. CRBU | LENZ Therapeutics, Inc. LENZ | TScan Therapeutics, Inc. TCRX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $14.56M | $11.16M | $19.09M | $10.32M |
| Revenue growth (YoY) | +53.2% | +11.7% | n/a | +266.7% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | -251.6% | n/m | -477.5% | n/m |
| Net margin | -436.5% | n/m | -430.3% | n/m |
| Net income | -$63.53M | -$148.12M | -$82.13M | -$129.77M |
| EPS (Diluted) | -$0.28 | -$1.59 | -$2.85 | -$1.00 |
| Operating cash flow | -$18.92M | -$110.99M | -$69.17M | -$135.32M |
| Free cash flow | -$19.44M | -$112.35M | -$70.00M | -$139.73M |
| Cash & equivalents | $40.79M | $12.36M | $25.18M | $152.41M |
| Total assets | $112.58M | $175.37M | $305.88M | $228.79M |
| Total liabilities | $69.24M | $53.19M | $21.54M | $105.67M |
| Shareholders' equity | $43.35M | $122.17M | $284.34M | $123.12M |
| Return on year-end equity | -146.6% | -121.2% | -28.9% | -105.4% |
| Shares outstanding | 243.12M | 95.14M | 31.34M | n/a |
Revenue, most recent five fiscal years
| Fiscal year | Lineage Cell Therapeutics, Inc. | Caribou Biosciences, Inc. | LENZ Therapeutics, Inc. | TScan Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $14.56M Ended 2025-12-31 | $11.16M Ended 2025-12-31 | $19.09M Ended 2025-12-31 | $10.32M Ended 2025-12-31 |
| 1 year earlier | $9.50M Ended 2024-12-31 | $9.99M Ended 2024-12-31 | $0 Ended 2024-12-31 | $2.82M Ended 2024-12-31 |
| 2 years earlier | $8.95M Ended 2023-12-31 | $34.48M Ended 2023-12-31 | n/a | $21.05M Ended 2023-12-31 |
| 3 years earlier | $14.70M Ended 2022-12-31 | $13.85M Ended 2022-12-31 | n/a | $13.54M Ended 2022-12-31 |
| 4 years earlier | $4.34M Ended 2021-12-31 | $9.60M Ended 2021-12-31 | n/a | $10.14M Ended 2021-12-31 |